About guselkuma b
Interleukin-23 inhibitor
Used for
- Moderate-to-severe plaque psoriasis
- Active psoriatic arthritis
- Moderate-to-severe ulcerative colitis
- Moderate-to-severe Crohn’s disease
Usual adult dose
Psoriasis or psoriatic arthritis: 100 mg under the skin at weeks 0 and 4, then every 8 weeks. Bowel disease: induction dosing differs by formulation and route; maintenance is typically 100 mg under the skin every 8 weeks.
Common side effects
- Upper respiratory infections
- Headache
- Injection-site reactions
- Joint pain
Important warnings
- Do not start during an active serious infection.
- Screen for tuberculosis before treatment; monitor for infection.
- Avoid live vaccines during treatment.
- Serious allergic reactions can occur.
Pregnancy
Human pregnancy information is limited; discuss potential benefits and risks with a healthcare professional.
Breastfeeding
It is not known whether guselkumab passes into human milk; discuss benefits and risks with a healthcare professional.
Interactions
- Live vaccines may cause infection and should be avoided.
- Other immune-suppressing medicines may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.